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In 1998, a group of phenotypically distinct neurons were discovered in the postero-lateral
hypothalamus which contained the neuropeptides hypocretin 1 and hypocretin 2 (also
called orexin A and orexin B), which are excitatory neuromodulators. Hypocretinergic
neurons project throughout the central nervous system and have been involved in the
generation and maintenance of wakefulness. The sleep disorder narcolepsy, characterized
by hypersomnia and cataplexy, is produced by degeneration of these neurons.
The hypocretinergic neurons are active during wakefulness in conjunction with the
presence of motor activity that occurs during survival-related behaviors. These neurons
decrease their ﬁring rate during non-REM sleep; however there is still controversy upon the
activity and role of these neurons during REM sleep. Hence, in the present report we
conducted a critical review of the literature of the hypocretinergic system during REM sleep,
and hypothesize a possible role of this system in the generation of REM sleep.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The basis for one of the most paradigmatic sleep disorders,
narcolepsy, has been partially solved. Nowadays, based on
animal and human research, i.e., a proliﬁc interaction
between basic and clinical data, it is known that the patho-
genesis of narcolepsy with cataplexy occurs as a result of the
degeneration of hypocretinergic (orexinergic) neurons within
the hypothalamus [1]. An autoimmune process may be
responsible for the degeneration of hypocretinergic neurons;ep. Production and Hosti
licenses/by-nc-nd/3.0/).
x3234.
Torterolo).
an Association of Sleepin fact, a recent study demonstrated the presence of CD4þT
cells that are reactive to hypocretin in patients with narco-
lepsy–cataplexy, which suggests a T cell-driven autoimmune
response [2]. However, there are still many questions about
the physiology of the hypocretinergic system.
The physiopathology of narcolepsy spins around two
main axes: the difﬁculty in maintaining wakefulness (hyper-
somnia, mainly in the form of sleep attacks) and an increase
in rapid eyes movements (REM) sleep. This is manifested
by a decrease in REM sleep latency or in intrusion ofng by Elsevier B.V. This is an open access article under the CC BY-
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paralysis, hypnagogic hallucinations) [1]. However, in spite of
the presence of hypersomnia, night sleep is also disrupted.
It is well-known that in the mesopontine tegmentum is
located the “necessary” and “sufﬁcient” neuronal network for
REM sleep generation [3–5]. This network is strongly modulated
by hypothalamic projections from the postero-lateral hypotha-
lamus, where hypocretinergic neurons are located (see below).
Consequently, in the present report, we will focus on the role of
the postero-lateral hypothalamus and its hypocretinergic neu-
rons in the generation and control of REM sleep.2. Hypocretinergic neurons, hypocretins and
receptors
Hypocretin (Hcrt) 1 and Hcrt 2 (also called orexin A and B)
were discovered in 1998 by two independent groups [6,7].
These neuropeptides are synthesized in a discrete group of
neurons (5000 in rodents, 11,000 in cat and 20–50,000 in
humans) in the postero-lateral hypothalamus [8,9]. Fig. 1
shows the characteristics and distribution of the hypocreti-
nergic neurons in the postero-lateral hypothalamus. Hcrts
exert their biological function through two metabotropic
receptors Hcrt-R1 and Hcrt-R2 (also known as orexin 1 and
2 receptors) that have broad and partially overlapping but
distinct patterns of distribution throughout the brain and
body. Through these receptors, Hcrts produce an excitatory
effect at the presynaptic and postsynaptic sites [1,8].Fig. 1 – Hypocretinergic neurons are intermingled with
MCHergic neurons in the postero-lateral hypothalamus.
(A) Photomicrographs of the postero-lateral hypothalamic
area of the cat. The sections were immunostained for
hypocretin (black, arrows) and MCH (brown, arrowheads).
Sections were processed utilizing the ABC method
and the DAB–H2O2 reaction to detect peroxidase activity.
This reaction was enhanced with nickel to label
hypocretinergic cells. Calibration bars: 50 μm. (B) Location
of MCHergic and hypocretinergic neurons in the postero-
lateral hypothalamus of a representative cat. Camera lucida
drawings of MCHergic (on the left, black circles) and
hypocretinergic neuronal bodies (on the right, red
circles) in the postero-lateral hypothalamus. The neurons
are from the same hemi-hypothalamus (reﬂected in the
ﬁgure). Camera lucida drawings were obtained from
adjacent sections that were immunostained for MCH for
Hcrt-2, respectively; these sections were counterstained
with Pyronin-Y. The demarcation and nomenclature
of cell groups in the cat hypothalamus are based on
Berman and Jones, as well as Bleier's work [105,106]. DM,
dorsomedial nucleus; EN, entopeduncular nucleus; fx,
fornix; HDA, dorsal hypothalamic area; HLA, lateral
hypothalamic area; INF, infundibular nucleus; mt,
mammillothalamic tract; PAH, paraventricular nucleus;
PEH, periventricular complex; PVH, parvocellular nucleus;
TCA, area of the tuber cinereum; VM, ventromedial
nucleus; ZI, zona incerta; 3V, third ventricle. Modiﬁed
from [9]. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version
of this article.)3. Postero-lateral hypothalamus
A logical ﬁrst step in determining the function of any discrete,
highly localized group of neurons, is to examine the beha-
viors and processes that are controlled by the site in the brain
wherein they reside. The postero-lateral hypothalamic area is
the key brain site that, for decades, has been identiﬁed as
being responsible for initiating, coordinating and maintaining
goal-oriented survival-type behaviors such as ﬁght, ﬂight and
food consumption among others [10–15]. In addition, and in
accordance with the preceding concept, experimental studies
have demonstrated that this area is critically involved in
controlling the following functions:
Sleep and wakefulness: Electrical or chemical activation of
the postero-lateral hypothalamus area results in wakefulness
accompanied by different patterns of somatomotor activity
(see below). Interestingly, chemical inhibition by muscimol (a
GABAA agonist) in this area decreases wakefulness and leads
to non-REM (NREM) sleep hypersomnia [16]. In addition, it
abolishes REM sleep. The preceding data suggests the pre-
sence of REM sleep inducing neurons within this area.
Somatomotor activity: Electrolytic lesions or chemical inhi-
bition of this region have been shown to produce a marked
decrease in locomotor activity, while electrical or chemical
activation produces an increase in motor activity [17–22]. It is
also well established that stimulation within the perifornical
lateral hypothalamic region initiates predatory activities and
that these behaviors are abolished or attenuated when this
hypothalamic site is lesioned [12].
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[13,23–25] is congruent with the site of the greatest concen-
tration of hypocretinergic neurons [26,27].
It is important to consider that, in addition to the hypo-
cretinergic neurons, other groups of neurons such as the
melanin concentrating-hormone (MCH) containing neurons
are present within this area [9]. The anatomical interrelation
between these groups of neurons is shown in Fig. 1.4. Afferents to hypocretinergic neurons
Hypocretinergic neurons receive inputs from several regions
such as the allocortex, many hypothalamic nuclei, periaqueduc-
tal gray matter, the dorsal raphe nucleus (DRN), and parabrachial
regions, which suggest that these neurons integrate a variety of
interoceptive, exteroceptive and homeostatic signals [28].
Several neurotransmitters act on hypocretinergic neurons
[29]. Glutamate depolarizes these neurons acting through AMPA
and NMDA receptors, and GABA inhibits these neurons through
GABAA and GABAB receptors. Neurotransmitters used by
neurons that form part of the activating systems [30], such as
serotonin, noradrenaline, acetylcholine and dopamine, modulate
the activity of hypocretinergic neurons. An in vitro study in mice
has shown that serotonin and noradrenaline hyperpolarize
hypocretinergic neurons through 5HT1A and α2 receptors,
respectively [29]. A weak depolarization mediated by α1 receptor
was also observed in the presence of a α2-receptor antagonist. In
rats, both noradrenaline and acetylcholine have a predominant
excitatory effect [31]. Carbachol (a mixed cholinergic agonist)
depolarizes 27% and hyperpolarizes 6% of the population of
hypocretinergic neurons in mice [29]; these effects are mediated
by different muscarinic receptors. Interestingly, histamine has
almost no effect on hypocretinergic neurons. D1 and D2 dopa-
mine receptors have opposing effects on excitatory presynaptic
terminals that impinge on hypocretinergic neurons [32].
The sleep-promoting factor, melanin-concentrating hor-
mone (MCH), inhibits hypocretinergic neurons (see below).5. Projections of the hypocretinergic neurons
Hypocretinergic neurons project throughout the central ner-
vous system [26]; furthermore, the activity of the peripheral
organs is also inﬂuenced by the Hcrts [33]. Hypocretinergic
neurons also have the potential to mediate complex func-
tions since they exhibit the morphology of prototypical
“command” neurons, which are small groups of highly
specialized cells that coordinate and integrate, in a comple-
mentary fashion, the activities of a vast number of neural and
hormonal systems [34–36].
Sensory and motor nuclei are directly innervated by hypo-
cretinergic neurons [37–40]. These neurons also project to the
thalamus and cortex [26], wherein they directly inﬂuence
thalamo-cortical activities that support cognitive functions.
Dense concentrations of hypocretin-containing axon terminals
are located in the tuberomammillary nucleus of the hypotha-
lamus, a waking-promoting area [41], as well as in brainstem
areas such as the laterodorsal and pedunculopontine tegmental
nucleus (LDT–PPT), locus coeruleus (LC) and DRN [26,42–44],that are known to participate in the control of sleep and
wakefulness [30].
We demonstrated that hypocretinergic neurons project to
the nucleus pontis oralis (NPO), which is considered to exert
executive control over the initiation and maintenance of REM
sleep [45]. A single injection of a cholinergic agonist, such as
carbachol, within the NPO of the cat, results in the generation
of a state that consists of all the behavioral and electro-
graphic signs of REM sleep with a very short latency (30 s to a
few minutes); this state lasts up to two hours (see below).6. Hypocretinergic neurons and wakefulness
Early studies revealed that the intraventricular injection of Hcrt
promotes wakefulness [46,47]. These data, as well as the fact that
the lack of hypocretinergic neurons in narcoleptic patients
induces hypersomnia [1], strongly suggested that this system
promotes wakefulness. However, by means of Fos technology
(the Fos protein is a marker of neuronal activity), we demon-
strated in the cat, that hypocretinergic neurons are not active
during wakefulness per se [48]. On the contrary, hypocretinergic
system becomes active during aroused wakefulness when the
animal is moving. In the absence of motor activity during alert
wakefulness, quiet wakefulness or quiet sleep, the hypocretiner-
gic system is not activated to any signiﬁcant extent [49]. In this
regard, several reports conﬁrmed that the hypocretinergic neu-
rons are involved in the promotion of somatomotor activity. The
data in Fig. 2 demonstrates that while Hcrt-containing neurons
do not express Fos during quiet wakefulness, they are active
during active wakefulness.
A detailed analysis of hypocretinergic neuronal activity
shows that these neurons are strongly activated when ani-
mals are exploring an unknown environment (exploratory
motor activity) [50]. In fact, in this study, the number of
HcrtþFosþneurons was approximately 10 times greater dur-
ing exploratory motor activity than during repetitive motor
activity that occurred during forced locomotion, even though
in both paradigms there was a comparable amount of motor
activity. Therefore, neither wakefulness nor motor activity
per se, were critical with respect to the activation of hypo-
cretinergic neurons. Therefore, we conclude that the hypo-
cretinergic system is engaged when animals are performing
goal (reward)-directed behaviors. In agreement with our
results, it was found that Hcrt knock-out mice were unable
to work for food or water reward during the light phase [51].
Recently, Chase presented the “Uniﬁed Survival Theory for
the Functioning of the Hypocretinergic System” [52]. The
basis of this theory is that the main role of the hypocretiner-
gic system is to initiate, coordinate and maintain survival
behaviors and survival-related processes.7. Hypocretinergic neurons and NREM sleep
The hypocretinergic neurons, as a component of the activat-
ing systems [30], do not participate in NREM sleep. In fact, we
demonstrated a lack of Fos expression in these neurons
during this behavioral state [49]. Subsequently, unit record-
ings conﬁrmed our early ﬁndings [53–55].
Fig. 2 – Photomicrographs illustrating hypocretin and Fos immunoreactive neurons from the postero-lateral area of the
hypothalamus. (A) Hypocretinergic neurons that express c-fos during active wakefulness with motor exploratory activity
(arrows). Hypocretinergic neurons are stained in brown. Fos immunoreactivity, which is shown in black, is restricted to
nuclei. Hcrt-Fosþ neurons (arrowheads) are also intermingled with HcrtþFosþneurons. (B) Group of hypocretinergic neurons
during quiet wakefulness. Hypocretinergic neurons did not express c-fos (unﬁlled arrowheads), although Hcrt-Fosþneurons
are intermingled with these neurons (ﬁlled arrowheads). All photomicrographs were taken from 20 lm-thick sections and
were processed with the diaminobenzidine method enhanced by nickel. Calibration bars: (A and B) 50 lm. Modiﬁed from [48].
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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There are presentations that argue that hypocretinergic
neurons are REM-OFF neurons and that these neurons inhibit
REM sleep. The REM-OFF proﬁle concept of the hypocretiner-
gic neurons arose based upon electrophysiological recordings
of identiﬁed hypocretinergic neurons [53–55]. Lee et al. [54]
recorded six hypocretinergic neurons in the hypothalamus of
the rat during unanesthesized semi-restricted conditions.
They found that the six neurons exhibited the largest ﬁring
rate during wakefulness, the rate decreased during NREM
sleep, and a nadir was reached during REM sleep. Another
study in rats [53], and a study in mice [55], demonstrated
similar ﬁring proﬁles.
However, an in-depth analysis of the preceding data
reveals that hypocretinergic neurons also discharge during
some “phasic” components of REM sleep. Fig. 2 of Lee et al.'s
[54] study illustrates the discharge of one representative
neuron; its ﬁring rate increases in relation to muscle twitches
during REM sleep as well as during REM sleep that precedes
awakening. In addition, their Fig. 2 shows that there is a burst
of ﬁring in a short period (just a couple of seconds) ofFig. 3 – (A) Polygraphic recording of an episode of REM sleep indu
(NPO) in the cat. Arrows signal the beginning of the microinjectio
for euthanasia. EEG, electroencephalogram; EOG, electro-oculogr
EMG, electromyogram. (B–D) Photomicrographs illustrate Fos im
postero-lateral area of the hypothalamus during REM sleep indu
brown. Fos immunoreactivity, which is shown in black, is restr
ABC method and the DAB–H2O2 reaction to detect peroxidase act
protein. Calibration bars: (B–D) 10 μm. Modiﬁed from [48]. (For int
reader is referred to the web version of this article.)“wakefulness” that is between two REM sleep periods (with-
out a preceding NREM sleep epoch). Amici et al., consider this
kind of episodes as a “cluster” type of REM sleep, instead of
two independent REM sleep episodes interrupted by an
episode of wakefulness [56,57]. Another study in rats also
acknowledged that hypocretinergic neurons “occasionally
discharge in phasic REM” [53]. In addition, in freely moving
mice, hypocretinergic neurons display transient discharges
during REM sleep [55]. Hence, at least some hypocretinergic
neurons increase their ﬁring rate during the phasic periods of
REM sleep. It would be important to examine the pattern of
activity of these neurons in an animal that exhibits robust
phasic periods of REM sleep, such as the cat [58].
Studies in the cat, strongly suggest that there is hypocreti-
nergic neuronal activity during REM sleep, probably during the
phasic events of this state. An increase in the number of
HcrtþFosþneurons was observed during REM sleep induced by
carbachol microinjections into the NPO [48]. In this study, REM
sleep was induced by carbachol microinjections in order to
generate a state of sufﬁciently long duration to allow Fos protein
to be synthesized in high concentration. Fig. 3A illustrates aced by carbachol microinjection into the nucleus pontis oralis
n of carbachol into the NPO as well as pentobarbital injection
am; LGN, lateral geniculate nucleus electrogram (PGO waves);
munoreactive hypocretinergic neurons (arrows) from the
ced by carbachol. Hypocretin immunoreaction is stained in
icted to the nuclei. Sections were processed employing the
ivity. This reaction was enhanced with nickel to label the Fos
erpretation of the references to color in this ﬁgure legend, the
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S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 9 – 2 924representative carbachol-induced period of REM sleep, which has
the same characteristics as natural REM sleep. During this state,
34% of the hypocretinergic neurons were activated according to
their Fos-expression; representative active “HcrtþFosþ” neurons
are shown in Fig. 3B. The distribution of the active hypocreti-
nergic neurons of a representative experiment is shown in Fig. 4.
This result is in agreement with the ﬁndings of Kiyashchenko
et al. [59]. Utilizingmicrodialysis in freely moving cats they found
an increase in Hcrt-1 release during REM sleep, both in the
hypothalamus and basal forebrain. Hence, this study also
indicates that hypocretinergic neurons are active during REM
sleep, probably in conjunction with phasic events.
Hypocretinergic activation during REM sleep is likely
related to the activation that occur during certain patterns
of somatomotor activity [50]. Although motor output is
inhibited at the motoneuron level during REM sleep, suprasp-
inal motor systems are very active during this state [60–62]. In
fact, in conjunction with PGO waves, a phasic event that
occurs during REM sleep, there is a potentiation of the REM
sleep-related hyperpolarization of motoneurons [3].
Microinjections studies also suggest that Hcrt may contri-
bute with some aspects of REM sleep. Hcrt-1 applied into the
gigantocellular nucleus and dorsal paragigantocellular nucleus
of the medullary reticular formation, which are sites that have
been previously identiﬁed that generate atonia by electrical
stimulation, produced bilateral hindlimb muscle atonia, similar
to which occurs during REM sleep atonia and cataplexy [63].
We demonstrated previously the presence of hypocreti-
nergic projections to the NPO, the REM sleep executive area in
the pons [45]. Microinjections of Hcrt-1 or Hcrt-2 into the NPO
of the cat increase the time spent in REM sleep and result in a
decrease in the latency to the generation of this state [64].
Furthermore, the juxtacellular application of Hcrt-1 results in
an increase in the excitability of NPO neurons, which is
associated with the induction of REM sleep [65]. In addition,
Hcrt-1 increases acetylcholine release in the NPO of the rat
[66,67]. In this regard, it is known that acetylcholine levels
within this region increase during REM sleep [68]. However, a
decrease in REM sleep when Hcrt-1 is microinjected into the
NPO of the cat was also described [69]. Furthermore, the
iontophoretic application of Hcrt-1 into the NPO of the rat
produces an inhibition of NPO neurons, which can be blocked
by previous iontophoretic application of bicuculline, a GABAA
receptors antagonist [70]. In fact, it has been shown that Hcrt
increases GABA levels in the NPO of the rat, and hypocretin
and GABA interact within this nucleus to promote wakeful-
ness [71,72]. The presence of Hcrt-2 receptors on GABAergic
neurons within the NPO may be the cellular basis for this
effect [73].
The paradoxical or contradictory ﬁndings involving the
REM sleep and wakefulness promoting actions of Hcrt within
the NPO were reconciled by Xi and Chase [74]. They demon-
strated that the microinjections of Hcrt-1 within the NPO
generate REM sleep when applied during NREM sleep, but
promote wakefulness when applied during this behavioral
state. Thus, the behavioral state of the animal at the time of
the application of Hcrt determines whether REM sleep or
wakefulness occurs.
It is attractive to note that hypocretinergic cells in the
hypothalamus may be involved in the control of both activewakefulness and REM sleep, and that within both patterns of
behavioral state control changes in motor activity play a
predominant role. This pattern of duality of behavioral state
control with opposite motor responses is reminiscent of the
phenomenon of Reticular Response-Reversal in the NPO
[75,76]. This phenomenon involves mechanisms that result
in the facilitation of wakefulness and somatomotor activa-
tion during wakefulness, as well as the generation of REM
sleep and its accompanying pattern of motor inhibition
during this sleep state [75,76]. Reticular Response-Reversal
determines, for example, that auditory stimulation promotes
somatomotor activation during wakefulness, and also
increases the hyperpolarization of motoneurons and pro-
duces atonia during REM sleep [3].
It is well known that in the “twitches” that occur during
REM sleep, there is an increase in the frequency of moto-
neuron postsynaptic inhibitory potentials (IPSPs) that gener-
ate atonia compared with the tonic periods of REM sleep.
Paradoxically, there is also an important increase in excita-
tory drives (excitatory postsynaptic potentials, EPSPs) that
also impinge on motoneurons during “phasic” REM sleep.
Hence, there is a competition between these opposing forces
during phasic REM sleep; the winner determines whether
motoneurons discharge or remain silent [3]. Hypocretins are
likely related to this phenomenon; these peptides may facil-
itate motor activity during wakefulness and the phasic
components of REM sleep by direct actions onto motoneur-
ons (see below). Furthermore, throughout REM sleep, hypo-
cretinergic activation of the NPO generates motor inhibition
due to processes involving Reticular Response-Reversal pro-
cess [3,52].
In narcolepsy–cataplexy, there is an increase in the inci-
dence of REM sleep behavioral disorder (RBD) [77]. In RBD the
mechanisms that produce atonia are signiﬁcantly reduced,
which supports the hypothesis that the dysfunction of the
hypocretinergic system produces instability of motor regula-
tory systems during REM sleep.9. Working hypothesis 1: hypocretinergic
neurons are active during “phasic” REM sleep
EEG activation, theta activity in the hippocampus and muscle
atonia are the classic biomarkers for the identiﬁcation of REM
sleep. Accompanying these “tonic” signs are rapid eye move-
ments, muscle twitches, PGO waves, breathing irregularities
as well as heart rate and blood pressure increases that
constitute the phasic events of REM sleep. Other signs such
as acceleration of the theta rhythm also correlate with these
phasic events [78].
Experimental evidences suggest that while hypocretiner-
gic neurons turn off during “tonic” REM sleep, at least a
subset of these neurons discharge in burst during phasic REM
sleep [53–55]. Furthermore, during REM sleep induced by
carbachol, there is an activation of 34% of hypocretinergic
neurons [48]. In addition, Hcrt-1 synaptic release increases
during REM sleep [59]. These data suggest that hypocretiner-
gic neurons are active during the “phasic” component of REM
sleep (Fig. 5).
Fig. 5 – Schema of the working hypotheses 1 and 2. Hypocretinergic neurons not only are correlated with the “phasic”
components of REM sleep but also promote its generation.
Fig. 4 – Distribution of Fos and hypocretinergic neurons during active wakefulness with motor-exploratory activity, quiet
wakefulness and REM sleep induced by the microinjection of carbachol into the nucleus pontis oralis. The camera lucida
drawing shows the distribution of HcrtþFosþneurons. Each mark indicates one labeled neuron. The percentage of
HcrtþFosþneurons from the total number of hypocretinergic neurons was on average 79% for active wakefulness, 34% for
REM-carbachol and 2% for quiet wakefulness [48]. 3V, third ventricle; Fx, fornix.
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neurons are involved in the generation of the
“phasic” phenomena of REM sleep
If hypocretinergic neurons are active during “phasic” REM
sleep, they are likely to promote the phasic events of REM
sleep. Hypocretins directly activate motor nuclei, breathing
neuronal networks and sympathetic output that control the
cardiovascular system [40,79–81], as well as the medial
septum where the pacemaker for the hypocamppal theta
rhythm is located [82]. By these means, hypocretinergic
neurons promote the “phasic” components of REM sleep
(Fig. 5).
Yamuy et al. [40] demonstrated in lumbar motoneurons
that the juxtacellular administration of hypocretin-1 and
electrical activation of hypocretinergic neurons activate moto-
neurons. Therefore, it is likely that the “phasic” discharge ofhypocretinergic neurons during REM facilitates motoneuron
activity and muscle twitches. The intracerebroventricular
injection of either hypocretin 1 and 2 increases heart rate,
mean arterial pressure and renal sympathetic activity in
conscious rats [79]. Hypocretins stimulate breathing and
knocking-out the preprohypocretin gene in mice reduces
CO2-induced increases in breathing by 50% and increases the
frequency of spontaneous sleep apneas [81]. Lesions of medial
septum neurons by hypocretin-2 conjugated with the neuro-
toxin saporin abolishes theta rhythm of the hippocampus
during both active wakefulness and REM sleep, suggesting
that hypocretin facilitates theta rhythm generation [82]. All
these effects induced by hypocretin involve ergotropic or
energy-expending behaviors [52].
Although disturbances in the phasic components of REM
sleep occurs in narcolepsy–cataplexy and in hypocretin-
deﬁcient mice [83–85], new experimental approaches are
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cretins and “phasic” REM sleep.Fig. 6 – The yin and yang is the Taoist symbol used to
describe how polar or seemingly contrary forces are
interconnected and interdependent in the natural world,
and how they give rise to each other in turn. This concept
could be applied to the opposite but complementary role of
hypocretin and melanin-concentrating hormone (MCH) in
the control of wakefulness and sleep. Hypocretin (HCRT) an
excitatory neuropeptide, and MCH an inhibitory
neuropeptide, interact both at the lateral hypothalamic level
as well as in the activating and hypnogenic neuronal areas,
in order to regulate the generation of the sleep and
wakefulness cycle.11. Working hypothesis 3: there are
complementary but opposite functions of
hypocretin and MCH in the control of REM sleep
Due to the importance of the MCHergic system in sleep
physiology [86,87], it is relevant to examine the interactions
between the MCHergic and the hypocretinergic systems. A
strong anatomical relationship exists between hypocretiner-
gic and MCHergic neurons in the hypothalamus. As it is
shown in Fig. 1, MCHergic neurons are intermingled with
Hcrt-containing neurons in the postero-lateral hypothala-
mus, mainly at the tuberal and tuberomammillar levels [9].
MCHergic ﬁbers are in close relationship with hypocretinergic
neurons and vice versa, which suggest the existence of
reciprocal synaptic contacts between both types of cells
[9,88]. This fact as well as the presence of hypocretinergic
receptors on MCHergic neurons indicates the existence of an
important functional interaction between both systems [89].
In this regard, Hcrt increases MCH mRNA expression in
hypothalamic neurons, directly excites MCHergic neurons
and increases glutamate release onto them [90,91]. On the
other hand, MCH modulates Hcrt-mediated effects on beha-
vioral state and synaptic transmission in the lateral hypotha-
lamus [92]. In addition, the efﬁcacy of glutamatergic synapses
on hypocretinergic neurons is enhanced in MCHR1 knockout
mice, and Hcrt-1-induced ﬁring is facilitated. On the contrary,
in wild-type mice, MCH signiﬁcantly attenuates Hcrt-1
induced enhancement of spike frequency in hypocretinergic
neurons, but not its basal activity. Furthermore, in these
neurons, MCH attenuates Hcrt-1-induced enhancement of
the frequency of miniature excitatory postsynaptic currents.
These effects imply that MCH exerts a unique inhibitory
inﬂuence on hypocretinergic signaling as a way to ﬁne-tune
the output of these neurons.
Interestingly, hypocretinergic and MCHergic neurons
respond in a different way to most homeostatic signals such
as glucose [93] or to waking-related neurotransmitters such
as noradrenaline [31]. It is of note that while hypocretinergic
neurons of the rat mainly express α1 adrenergic receptors,
MCHergic neurons express the α2 adrenergic receptors, which
are related to activation or inhibition of their targets, respec-
tively [94].
We have shown that both hypocretinergic and MCHergic
neurons project to the NPO [45,95]. In addition, ﬁbers and
terminals of both systems are highly intermingled, which
suggests the presence of important interactions between
these systems within their mesopontine targets, similar to
the anatomical and functional interactions that have been
described within the hypothalamus (see above).
Several studies suggest that MCHergic neurons are
involved in the generation of sleep, especially REM sleep
[86,87]. These neurons discharge in a reciprocal manner to
hypocretinergic neurons across the sleep–wake cycle. MCHer-
gic neurons have a high ﬁring rate during tonic REM sleep, but
do not increase their ﬁring level during “phasic” REM sleep
[96]. When MCH is microinjected in the area where REM-carbachol is generated, it produces an increase in time that
the animals spend in REM sleep together with a decrease in
the latency to this behavioral state [95]. MCH also exerts its
REM sleep promoting functions acting through the DRN
[97,98], where it exerts an inhibitory role on serotonergic
neurons [99,100].
Interestingly, MCH blunts the central regulation of sympa-
thetic tone and adaptive sympathetic reﬂexes, and decreases
metabolism [101–103]. These are trophotropic or energy-
conserving effects, which are opposite to the effects produced
by the hypocretinergic system (see above).
These experimental data are the basis for the hypothesis
that while MCHergic neurons are active during tonic REM
sleep and promote this “quiescent” behavioral state, hypo-
cretinergic neurons are active during “phasic” REM sleep
and induce (at least partially) phasic episodes of this state
(see Fig. 6).12. Research agenda
In order to conﬁrm the relationship between the hypocretins
and the “phasic” episodes of REM sleep, additional experi-
mental data are needed. Electrophysiological recording stu-
dies would be important to conduct in different species in
order to correlate hypocretinergic discharge during REM sleep
and the different aspects of the “phasic” components of REM
sleep. In addition, studies of the effect on “phasic” REM sleep
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 9 – 2 9 27of activating or blocking the hypocretinergic system during
REM sleep, for example by means of optogenetic stimulation
[104] or by the administration of hypocretin agonists or
antagonists, would be important to conﬁrm our hypotheses.
Similar approaches are also necessary to demonstrate that
MCH plays a proactive role in “tonic” REM sleep but not in
“phasic” REM sleep.13. Conclusions
In the present report we reviewed the role of the hypocreti-
nergic neurons in REM sleep generation. Experimental evi-
dences suggest that these neurons are active during the
“phasic” episodes of REM sleep and we hypothesize that they
may be involved in the induction of these episodes. In
addition, we consider that, by modulation of mesopontine
networks such as those involving cholinergic neurons of the
LDT–PPT, the monoaminergic neurons of the DRN and LC,
and especially through the NPO, the executive area for REM
sleep generation, MCHergic and hypocretinergic neurons
induces “tonic” (trophotropic) and “phasic” (ergotropic) REM
sleep states, respectively.Acknowledgments
This work was partially supported by the “Programa de
Desarrollo de Ciencias Básicas, PEDECIBA” and by the ANII-
FCE-2–2011-1-7030 grant from Uruguay.
r e f e r e n c e s
[1] Mignot E. Narcolepsy: pathophysiology and genetic
predisposition. In: Krieger MH, Roth T, Dement W,
Principles and practices of sleep medicine. Philadelphia:
Saunders; 2011. p. 938–56.
[2] De la Herran-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L,
Hou T, et al. CD4þ T cell autoimmunity to hypocretin/orexin
and cross-reactivity to a 2009 H1N1 influenza A epitope in
narcolepsy. Sci Transl Med 2013;5:216ra176.
[3] Chase MH. Motor control during sleep and wakefulness:
clarifying controversies and resolving paradoxes. Sleep Med
Rev 2013;17:299–312.
[4] Luppi PH, Clement O, Fort P. Paradoxical (REM) sleep genesis
by the brainstem is under hypothalamic control. Curr Opin
Neurobiol 2013;23:786–92.
[5] Siegel JM. REM sleep. In: Kryger MH, Roth T, Dement WC,
Principles and practices of sleep medicine. Philadelphia:
Elsevier-Saunders; 2005. p. 120–35.
[6] de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson
PE, et al. The hypocretins: hypothalamus-specific peptides
with neuroexcitatory activity. Proc Natl Acad Sci USA
1998;95:322–7.
[7] Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM,
Tanaka H, et al. Orexins and orexin receptors: a family of
hypothalamic neuropeptides and G protein-coupled
receptors that regulate feeding behavior. Cell 1998;92:573–85.
[8] Li J, Hu Z, de Lecea L. The hypocretins/orexins: integrators of
multiple physiological functions. Br J Pharmacol 2013.
[9] Torterolo P, Sampogna S, Morales FR, Chase MH. MCH-
containing neurons in the hypothalamus of the cat:searching for a role in the control of sleep and wakefulness.
Brain Res 2006;1119:101–14.
[10] Bernardis LL, Bellinger LL. The lateral hypothalamic area
revisited: ingestive behavior. Neurosci Biobehav Rev
1996;20:189–287.
[11] Anand BK, Brobeck JR. Localization of a feeding center in the
hypothalamus of the rat. Proc Soc Exp Biol Med
1951;77:323–4.
[12] Gregg TR, Siegel A. Brain structures and neurotransmitters
regulating aggression in cats: implications for human
aggression. Prog Neuropsychopharmacol Biol Psychiatry
2001;25:91–140.
[13] Clemente CD, Chase MH. Neurological substrates of
aggressive behavior. Annu Rev Physiol 1973;35:329–56.
[14] Hess WR. The diencephalon. New York: Grune and Stratton;
1954.
[15] Swanson LW. The hypothalamus. In: Bjorklund A, Hokfelt T,
Swanson LW, Handbook of chemical neuroanatomy, vol. 5.
Elsevier; 1987. p. 1–124.
[16] Lin JS, Sakai K, Vanni-Mercier G, Jouvet M. A critical role of
the posterior hypothalamus in the mechanisms of
wakefulness determined by microinjection of muscimol in
freely moving cats. Brain Res 1989;479:225–40.
[17] Gladfelter WE, Brobeck JR. Decreased spontaneous
locomotor activity in the rat induced by hypothalamic
lesions. Am J Physiol 1962;203:811–7.
[18] Blake DJ, Gladfelter WE. Wheel-running activity after kainic
acid injection into lateral hypothalamus of rats. Physiol
Behav 1986;36:1009–16.
[19] Wardas J, Ossowska K, Wolfarth S. Evidence for the
independent role of GABA synapses of the zona incerta-
lateral hypothalamic region in haloperidol-induced
catalepsy. Brain Res 1988;462:378–82.
[20] Marciello M, Sinnamon HM. Locomotor stepping initiated by
glutamate injections into the hypothalamus of the
anesthetized rat. Behav Neurosci 1990;104:980–90.
[21] Sinnamon HM, Lee SH, Adams DB, Stopford CK. Locomotor
stepping elicited by electrical stimulation of the lateral
hypothalamus requires an ipsilateral descending pathway.
Physiol Behav 1984;33:209–15.
[22] Shekhar A, DiMicco JA. Defense reaction elicited by injection
of GABA antagonists and synthesis inhibitors into the
posterior hypothalamus in rats. Neuropharmacology
1987;26:407–17.
[23] Olds J. Self-stimulation of the brain; its use to study local
effects of hunger, sex, and drugs. Science 1958;127:315–24.
[24] Margules DL, Olds J. Identical feeding and rewarding systems
in the lateral hypothalamus of rats. Science 1962;135:374–5.
[25] Wyrwicka W, Clemente CD, Chase MH. Hypothalamic
substrates of self-stimulation in cats. Exp Neurol
1986;93:557–64.
[26] Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC,
Sutcliffe JG, et al. Neurons containing hypocretin (orexin)
project to multiple neuronal systems. J Neurosci
1998;18:9996–10015.
[27] Zhang JH, Sampogna S, Morales FR, Chase MH. Orexin
(hypocretin)-like immunoreactivity in the cat hypo-
thalamus: a light and electron microscopic study. Sleep
2001;24:1–10.
[28] Yoshida K, McCormack S, Espana RA, Crocker A, Scammell
TE. Afferents to the orexin neurons of the rat brain. J Comp
Neurol 2006;494:845–61.
[29] Yamanaka A. Afferent system of orexin neurons. In: Nishino
S, Sakurai T, The orexin/hypocretin system. Physiology and
pathophysiology. Totowa (New Jersey): Humana Press; 2006.
p. 61–70.
[30] Torterolo P, Vanini G. New concepts in relation to generating
and maintaining arousal. Rev Neurol 2010;50:747–58.
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 9 – 2 928[31] Bayer L, Eggermann E, Serafin M, Grivel J, Machard D,
Muhlethaler M, et al. Opposite effects of noradrenaline and
acetylcholine upon hypocretin/orexin versus melanin
concentrating hormone neurons in rat hypothalamic slices.
Neuroscience 2005;130:807–11.
[32] Alberto CO, Trask RB, Quinlan ME, Hirasawa M. Bidirectional
dopaminergic modulation of excitatory synaptic
transmission in orexin neurons. J Neurosci 2006;26:
10043–50.
[33] Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M. Orexins
and their receptors: structural aspects and role in peripheral
tissues. Cell Mol Life Sci 2003;60:72–87.
[34] Kerman IA. Organization of brain somatomotor-sympathetic
circuits. Exp Brain Res 2008;187:1–16.
[35] Oldfield BJ, Allen AM, Davern P, Giles ME, Owens NC. Lateral
hypothalamic ‘command neurons’ with axonal projections
to regions involved in both feeding and thermogenesis. Eur J
Neurosci 2007;25:2404–12.
[36] Kupfermann I, Weiss K. The command neuron concept.
Behav Brain Sci 1978;1:3–39.
[37] McGregor R, Damian A, Fabbiani G, Torterolo P, Pose I, Chase
M, et al. Direct hypothalamic innervation of the trigeminal
motor nucleus: a retrograde tracer study. Neuroscience
2005;136:1073–81.
[38] Torterolo P, Vanini G, Zhang J, Sampogna S, Chase M.
Hypocretinergic fibers and receptors in the inferior
colliculus. Sleep 2007;30:A15.
[39] Fung SJ, Yamuy J, Sampogna S, Morales FR, Chase MH.
Hypocretin (orexin) input to trigeminal and hypoglossal
motoneurons in the cat: a double-labeling
immunohistochemical study. Brain Res 2001;903:257–62.
[40] Yamuy J, Fung SJ, Xi M, Chase MH. Hypocretinergic control of
spinal cord motoneurons. J Neurosci 2004;24:5336–45.
[41] Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/
hypocretin excites the histaminergic neurons of the
tuberomammillary nucleus. J Neurosci 2001;21:9273–9.
[42] Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T,
Lee C, et al. Narcolepsy in orexin knockout mice: molecular
genetics of sleep regulation. Cell 1999;98:437–51.
[43] Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S,
Kangawa K, et al. Orexins, orexigenic hypothalamic peptides,
interact with autonomic, neuroendocrine and
neuroregulatory systems. Proc Natl Acad Sci USA
1999;96:748–53.
[44] Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M,
Goto K. Distribution of orexin neurons in the adult rat brain.
Brain Res 1999;827:243–60.
[45] Torterolo P, Sampogna S, Chase MH. Hypocretinergic and
non-hypocretinergic projections from the hypothalamus to
the REM sleep executive area of the pons. Brain Res
2013;1491:68–77.
[46] Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S,
et al. Orexin A activates locus coeruleus cell firing and
increases arousal in the rat. Proc Natl Acad Sci USA
1999;96:10911–6.
[47] Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain
neuropeptide, orexin-A, modulates the sleep–wake cycle of
rats. Eur J Neurosci 2000;12:726–30.
[48] Torterolo P, Yamuy J, Sampogna S, Morales FR, Chase MH.
Hypothalamic neurons that contain hypocretin (orexin)
express c-fos during active wakefulness and carbachol-
induced active sleep. Sleep Res Online 2001;4:25–32. 〈http://
www.sro.org/2001/Torterolo/25〉.
[49] Torterolo P, Yamuy J, Sampogna S, Morales FR, Chase MH.
Hypocretinergic neurons are primarily involved in activation
of the somatomotor system. Sleep 2003;1:25–8.
[50] Torterolo P, Ramos OV, Sampogna S, Chase MH.
Hypocretinergic neurons are activated in conjunction withgoal-oriented survival-related motor behaviors. Physiol
Behav 2011;104:823–30.
[51] McGregor R, Wu MF, Barber G, Ramanathan L, Siegel JM.
Highly specific role of hypocretin (orexin) neurons:
differential activation as a function of diurnal phase, operant
reinforcement versus operant avoidance and light level. J
Neurosci 2011;31:15455–67.
[52] Chase MH. A unified survival theory of the functioning of the
hypocretinergic system. J Appl Physiol 2013.
[53] Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral
correlates of activity in identified hypocretin/orexin neurons.
Neuron 2005;46:787–98.
[54] Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/
hypocretin neurons across the sleep–waking cycle. J
Neurosci 2005;25:6716–20.
[55] Takahashi K, Lin JS, Sakai K. Neuronal activity of orexin and
non-orexin waking-active neurons during wake–sleep states
in the mouse. Neuroscience 2008;153:860–70.
[56] Amici R, Domeniconi R, Jones CA, Morales-Cobas G, Perez E,
Tavernese L, et al. Changes in REM sleep occurrence due to
rhythmical auditory stimulation in the rat. Brain Res
2000;868:241–50.
[57] Amici R, Morales-Cobas G, Jones CA, Perez E, Torterolo P,
Zamboni G, et al. REM sleep enhancement due to rhythmical
auditory stimulation in the rat. Behav Brain Res
2001;123:155–63.
[58] Ursin R, Sterman M. Manual for standardized scoring of
sleep and waking states in adult cats. Los Angeles: BIS/BRI,
University of California; 1981.
[59] Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu
MF, John J, et al. Release of hypocretin (orexin) during waking
and sleep states. J Neurosci 2002;22:5282–6.
[60] Fung SJ, Yamuy J, Sampogna S, Morales FR, Chase MH. Orexin
(hypocretin) input to trigeminal and hypoglossal
motoneurons in the cat. Soc Neurosci 2000;26:693.
[61] Chase MH, Morales FR. Subthreshold excitatory activity and
motoneuron discharge during REM periods of active sleep.
Science 1983;221:1195–8.
[62] Nakamura Y, Goldberg LJ, Chandler SH, Chase MH.
Intracellular analysis of trigeminal motoneuron activity
during sleep in the cat. Science 1978;199:204–7.
[63] Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Muscle tone
facilitation and inhibition after orexin-a (hypocretin-1)
microinjections into the medial medulla. J Neurophysiol
2002;87:2480–9.
[64] Xi MC, Fung SJ, Yamuy J, Morales FR, Chase MH. Induction of
active (REM) sleep and motor inhibition by hypocretin in the
nucleus pontis oralis of the cat. J Neurophysiol
2002;87:2880–8.
[65] Xi MC, Fung SJ, Yamuy J, Morales FR, Chase MH.
Hypocretinergic facilitation of synaptic activity of neurons in
the nucleus pontis oralis of the cat. Brain Res 2003;976:253–8.
[66] Bernard R, Lydic R, Baghdoyan HA. Hypocretin-1 causes G
protein activation and increases ACh release in rat pons. Eur
J Neurosci 2003;18:1775–85.
[67] Bernard R, Lydic R, Baghdoyan HA. Hypocretin (orexin)
receptor subtypes differentially enhance acetylcholine
release and activate g protein subtypes in rat pontine
reticular formation. J Pharmacol Exp Ther 2006;317:163–71.
[68] Kodama T, Takahashi Y, Honda Y. Enhancement of
acetylcholine release during paradoxical sleep in the dorsal
tegmental field of the cat brain stem. Neurosci Lett
1990;114:277–82.
[69] Moreno-Balandran E, Garzon M, Bodalo C, Reinoso-Suarez F,
de Andres I. Sleep-wakefulness effects after microinjections
of hypocretin 1 (orexin A) in cholinoceptive areas of
the cat oral pontine tegmentum. Eur J Neurosci
2008;28:331–41.
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 9 – 2 9 29[70] Nunez A, Moreno-Balandran ME, Rodrigo-Angulo ML, Garzon
M, De Andres I. Relationship between the perifornical
hypothalamic area and oral pontine reticular nucleus in the
rat. Possible implication of the hypocretinergic projection in
the control of rapid eye movement sleep. Eur J Neurosci
2006;24:2834–42.
[71] Watson CJ, Soto-Calderon H, Lydic R, Baghdoyan HA. Pontine
reticular formation (PnO) administration of hypocretin-1
increases PnO GABA levels and wakefulness. Sleep
2008;31:453–64.
[72] Brevig HN, Watson CJ, Lydic R, Baghdoyan HA. Hypocretin
and GABA interact in the pontine reticular formation to
increase wakefulness. Sleep 2011;33:1285–93.
[73] Brischoux F, Mainville L, Jones BE. Muscarinic-2 and orexin-2
receptors on GABAergic and other neurons in the rat
mesopontine tegmentum and their potential role in sleep–
wake state control. J Comp Neurol 2008;510:607–30.
[74] Xi M, Chase MH. The injection of hypocretin-1 into the
nucleus pontis oralis induces either active sleep or
wakefulness depending on the behavioral state when it is
administered. Sleep 2010;33:1236–43.
[75] Chase MH, Babb M. Masseteric reflex response to reticular
stimulation reverses during active sleep compared with
wakefulness or quiet sleep. Brain Res 1973;59:421–6.
[76] Chase MH, Morales FR. The atonia and myoclonia of active
(REM) sleep. Annu Rev Psychol 1990;41:557–84.
[77] Knudsen S, Gammeltoft S, Jennum PJ. Rapid eye movement
sleep behaviour disorder in patients with narcolepsy is
associated with hypocretin-1 deficiency. Brain
2010;133:568–79.
[78] Rowe K, Moreno R, Lau TR, Wallooppillai U, Nearing BD,
Kocsis B, et al. Heart rate surges during REM sleep are
associated with theta rhythm and PGO activity in cats. Am J
Physiol 1999;277:R843–9.
[79] Shirasaka T, Kunitake T, Takasaki M, Kannan H. Neuronal
effects of orexins: relevant to sympathetic and
cardiovascular functions. Regul Pept 2002;104:91–5.
[80] Zhang W, Fukuda Y, Kuwaki T. Respiratory and
cardiovascular actions of orexin-A in mice. Neurosci Lett
2005;385:131–6.
[81] Williams RH, Burdakov D. Hypothalamic orexins/hypocretins
as regulators of breathing. Expert Rev Mol Med 2008;10:e28.
[82] Gerashchenko D, Salin-Pascual R, Shiromani PJ. Effects of
hypocretin-saporin injections into the medial septum on
sleep and hippocampal theta. Brain Res 2001;913:106–15.
[83] Vankova J, Nevsimalova S, Sonka K, Spackova N, Svejdova-
Blazejova K. Increased REM density in narcolepsy–cataplexy
and the polysymptomatic form of idiopathic hypersomnia.
Sleep 2001;24:707–11.
[84] Geisler P, Meier-Ewert K, Matsubayshi K. Rapid eye
movements, muscle twitches and sawtooth waves in the
sleep of narcoleptic patients and controls.
Electroencephalogr Clin Neurophysiol 1987;67:499–507.
[85] Silvani A, Bastianini S, Berteotti C, Lo Martire V, Zoccoli G.
Control of cardiovascular variability during undisturbed
wake–sleep behavior in hypocretin-deficient mice. Am J
Physiol: Regul Integr Comp Physiol 2012;302:R958–64.
[86] Torterolo P, Lagos P, Monti JM. Melanin-concentrating hormone
(MCH): a new sleep factor? Front Neurol 2011;2:1–12.
[87] Monti JM, Torterolo P, Lagos P. Melanin-concentrating
hormone control of sleep–wake behavior. Sleep Med Rev
2013;17:293–8.
[88] Guan JL, Uehara K, Lu S, Wang QP, Funahashi H, Sakurai T, et
al. Reciprocal synaptic relationship between orexin-and
melanin-concentrating hormone-containing neurons in the
rat lateral hypothalamus: a novel circuit implicated in
feeding regulation. Int J Obes Relat Metab Disord
2002;26:1523–32.[89] Backberg M, Hervieu G, Wilson S, Meister B. Orexin receptor-1
(OX-R1) immunoreactivity in chemically identified neurons of
the hypothalamus: focus on orexin targets involved in control of
food and water intake. Eur J Neurosci 2002;15:315–28.
[90] Bayer L, Mairet-Coello G, Risold PY, Griffond B. Orexin/
hypocretin neurons: chemical phenotype and possible
interactions with melanin-concentrating hormone neurons.
Regul Pept 2002;104:33–9.
[91] van den Pol AN, Acuna-Goycolea C, Clark KR, Ghosh PK.
Physiological properties of hypothalamic MCH neurons
identified with selective expression of reporter gene after
recombinant virus infection. Neuron 2004;42:635–52.
[92] Rao Y, LuM, Ge F, Marsh DJ, Qian S,Wang AH, et al. Regulation of
synaptic efficacy in hypocretin/orexin-containing neurons by
melanin concentrating
hormone in the lateral hypothalamus. J Neurosci
2008;28:9101–10.
[93] Burdakov D, Gerasimenko O, Verkhratsky A. Physiological
changes in glucose differentially modulate the excitability of
hypothalamic melanin-concentrating hormone and orexin
neurons in situ. J Neurosci 2005;25:2429–33.
[94] Modirrousta M, Mainville L, Jones BE. Orexin and MCH
neurons express c-Fos differently after sleep deprivation vs.
recovery and bear different adrenergic receptors. Eur J
Neurosci 2005;21:2807–16.
[95] Torterolo P, Sampogna S, Chase MH. MCHergic projections to
the nucleus pontis oralis participate in the control of active
(REM) sleep. Brain Res 2009;1268:76–87.
[96] Hassani OK, Lee MG, Jones BE. Melanin-concentrating
hormone neurons discharge in a reciprocal manner to orexin
neurons across the sleep–wake cycle. Proc Natl Acad Sci USA
2009;106:2418–22.
[97] Lagos P, Torterolo P, Jantos H, Chase MH, Monti JM. Effects on
sleep of melanin-concentrating hormone microinjections
into the dorsal raphe nucleus. Brain Res 2009;1265:103–10.
[98] Lagos P, Torterolo P, Jantos H, Chase MH, Monti JM.
Immunoneutralization of melanin-concentrating hormone
(MCH) in the dorsal raphe nucleus: effects on sleep and
wakefulness. Brain Res 2011;1369:112–8.
[99] Urbanavicius J, Lagos P, Torterolo P, Scorza C. Role of melanin
concentrating hormone (MCH) on the dorsal raphe nucleus
(DRN): its relevance for depression. J Neurochem
2013;125:265.
[100] Pascovich C, Devera A, Lagos P, Costa A, Falconi A, Torterolo
P. Melanin-concentrating hormone (MCH) decreases
presumed serotonergic neuronal activity in the dorsal and
median raphe nucleus. Proceedings of the congreso de la
sociedad Argentina de neurociencias. Huerta Grande
(Argentina); 2011.
[101] Saito Y, Nagasaki H. The melanin-concentrating hormone
system and its physiological functions. Results Probl Cell
Differ 2008;46:159–79.
[102] Messina MM, Overton JM. Cardiovascular effects of
melanin-concentrating hormone. Regul Pept
2007;139:23–30.
[103] Egwuenu EJ, Fong AY, Pilowsky PM. Intrathecal melanin-
concentrating hormone reduces sympathetic tone and
blocks cardiovascular reflexes. Am J Physiol: Regul Integr
Comp Physiol 2005;303:R624–32.
[104] Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de
Lecea L. Neural substrates of awakening probed with
optogenetic control of hypocretin neurons. Nature
2007;450:420–4.
[105] Berman AL, Jones EG. The thalamus and basal telencephalum
of the cat. A citoarchitectonic atlas with stereotaxic
coordinates. Madison: University of Wisconsin; 1982.
[106] Bleier R. The hypothamus of the cat. Baltimore (MD): The
John Hopkins Press; 1961.
